Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

26.99
+0.88003.37%
Volume:855.56K
Turnover:22.31M
Market Cap:2.19B
PE:-5.89
High:27.26
Open:25.31
Low:24.54
Close:26.11
Loading ...

Beam Therapeutics Appoints Sravan Emany as CFO

MT Newswires Live
·
06 Dec 2024

Beam Therapeutics Names Sravan Emany Chief Financial Officer

Dow Jones
·
06 Dec 2024

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

THOMSON REUTERS
·
06 Dec 2024

Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?

Zacks
·
06 Dec 2024

Beam Therapeutics Strengthens Board with Pharma Veteran

TIPRANKS
·
04 Dec 2024

Beam Therapeutics Expands Its Board of Directors With Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

THOMSON REUTERS
·
04 Dec 2024

Press Release: Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Dow Jones
·
04 Dec 2024

CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?

Zacks
·
20 Nov 2024

Watch Out: 5 Altcoins in South Korea See Trading Volume Boom – Here’s the List

CoinMarketCap
·
18 Nov 2024

Daily Market Review: BTC, ETH, RAY, MATIC, BEAM

CoinMarketCap
·
09 Nov 2024

Beam Therapeutics upgraded to Outperform from Market Perform at Leerink

TipRanks
·
07 Nov 2024

Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Nov 2024

Stock Track | Beam Therapeutics Soars on Promising Sickle Cell Therapy Data and Preclinical Achievements

Stock Track
·
07 Nov 2024

Beam Therapeutics Gets Upgrade From Leerink Partners; Shares Rise

MT Newswires Live
·
07 Nov 2024

Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates

Zacks
·
07 Nov 2024

RBC Capital Adjusts Price Target on Beam Therapeutics to $24 From $27, Maintains Sector Perform, Speculative Risk Rating

MT Newswires Live
·
06 Nov 2024